마이코플라스마 검사 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global mycoplasma testing market size is expected to reach USD 4184.59 Million in 2034 from USD 1264.66 Million in 2025, growing at a CAGR of 14.22% during 2026-2034.The global mycoplasma testing market has expanded as biotechnology and pharmaceutical industries focus on ensuring product safety and quality. Mycoplasma are small bacteria that can contaminate cell cultures used in biological research and drug production. Testing for mycoplasma contamination is essential in laboratories and manufacturing facilities to prevent compromised research results and unsafe medical products.

Market growth is driven by increasing biopharmaceutical production and stricter regulatory requirements for product safety. Pharmaceutical companies and research institutions rely on advanced testing technologies to detect contamination quickly and accurately. Improvements in molecular diagnostic methods have enhanced testing efficiency and sensitivity.

The future outlook for the mycoplasma testing market remains positive as biotechnology research continues to expand. Innovations in automated testing systems and rapid detection methods may improve laboratory productivity. Increasing investments in cell-based therapies and vaccine development are also expected to drive demand for reliable contamination testing technologies.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product

• Instruments
• Kits & Reagents
• Services

By Technology

• PCR
• ELISA
• Direct Assay
• Indirect Assay
• Microbial Culture Techniques
• Enzymatic Methods

By Application

• Cell Line Testing
• Virus Testing
• End of Production Cells Testing
• Others

By End-use

• Academic Research Institutes
• Cell Banks
• Contract Research Organizations
• Pharmaceutical & Biotechnology Companies
• Others

COMPANIES PROFILED

• Thermo Fisher Scientific Inc., Merck KGaA, Charles River Laboratories International Inc., Lonza Group AG, Sartorius AG, Eurofins Scientific SE, Roche Diagnostics / F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., bioMerieux SA, Asahi Kasei Medical Co., Ltd., Bio-Rad Laboratories, Inc., QIAGEN N.V., PromoCell GmbH, Minerva Biolabs GmbH, InvivoGen, Rapid Micro Biosystems, Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MYCOPLASMA TESTING MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Kits & Reagents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MYCOPLASMA TESTING MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Technology
• 5.2. PCR Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. ELISA Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Direct Assay Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Indirect Assay Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Microbial Culture Techniques Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Enzymatic Methods Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MYCOPLASMA TESTING MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Cell Line Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Virus Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. End of Production Cells Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MYCOPLASMA TESTING MARKET: BY END-USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-use
• 7.2. Academic Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Cell Banks Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Contract Research Organizations Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Pharmaceutical & Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL MYCOPLASMA TESTING MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product
  • 8.2.2 By Technology
  • 8.2.3 By Application
  • 8.2.4 By End-use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product
  • 8.3.2 By Technology
  • 8.3.3 By Application
  • 8.3.4 By End-use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Spain
  • 8.3.10 Russia
  • 8.3.11 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product
  • 8.4.2 By Technology
  • 8.4.3 By Application
  • 8.4.4 By End-use
  • 8.4.5 China
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 India
  • 8.4.9 Australia
  • 8.4.10 South East Asia
  • 8.4.11 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product
  • 8.5.2 By Technology
  • 8.5.3 By Application
  • 8.5.4 By End-use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product
  • 8.6.2 By Technology
  • 8.6.3 By Application
  • 8.6.4 By End-use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL MYCOPLASMA TESTING INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Thermo Fisher Scientific Inc
  • 10.2.2 Merck KGaA
  • 10.2.3 Charles River Laboratories International Inc
  • 10.2.4 Lonza Group AG
  • 10.2.5 Sartorius AG
  • 10.2.6 Eurofins Scientific SE
  • 10.2.7 Roche Diagnostics / F. Hoffmann-La Roche Ltd
  • 10.2.8 Agilent Technologies Inc
  • 10.2.9 BioMerieux SA
  • 10.2.10 Asahi Kasei Medical Co.Ltd
  • 10.2.11 Bio-Rad LaboratoriesInc
  • 10.2.12 QIAGEN N.V
  • 10.2.13 PromoCell GmbH
  • 10.2.14 Minerva Biolabs GmbH
  • 10.2.15 InvivoGen
  • 10.2.16 Rapid Micro BiosystemsInc